DeutschNewstral
Article
Bbarrons.com on 2016-09-14 19:56
Sarepta Rally Has Legs as FDA Critic Leaves Agency
Related news
- MSarepta Therapeutics shares jump on news of critic’s departure from FDAmarketwatch.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
- BSarepta Slammed by FDA, Stock Is Now Intriguingbarrons.com
- BSlim Sarepta Hopes Rest With Top FDA Officialbarrons.com
- BSarepta Still a Buy After Expedited FDA Approvalbarrons.com
- BSarepta Jumps on FDA Delay but Remains a Buybarrons.com
- BSarepta Stock Is Spiking as FDA Reverses Course, Approving Drugbarrons.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- MSarepta stock falls on FDA concerns about drugmarketwatch.com
- MSarepta Therapeutics stock tanks after drug's FDA committee reviewmarketwatch.com
- MSarepta stock drops on erroneous adverse event report to FDAmarketwatch.com
- MSarepta stock drops after Muscular Dystrophy study halted by FDAmarketwatch.com
- BFor Sarepta and Muscular Dystrophy Patients, Today's FDA Hearing is Pivotal4 min readbarrons.com
- BSarepta Got a Scathing FDA Rejection and Its Stock Is Fallingbarrons.com
- MSarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugmarketwatch.com
Sarepta sells FDA review voucher for $125M, but analyst questions pricebizjournals.com- BSarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy. 2 min readbarrons.com
- MSarepta stock plummets 20% after FDA announces changes to investigational drug processmarketwatch.com
- BSarepta Therapeutics Stock Sinks as FDA Questions Newest Muscular Dystrophy Drugbarrons.com
- Sarepta gains after-hours as FDA accepts application for Duchenne drug approvalbizjournals.com